<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317846</url>
  </required_header>
  <id_info>
    <org_study_id>Trieste-study</org_study_id>
    <nct_id>NCT04317846</nct_id>
  </id_info>
  <brief_title>Transradial Evaluation Study of Diameter Increase After Vasodilatory Drugs Administration.</brief_title>
  <acronym>TRIESTE</acronym>
  <official_title>TransRadIal Evaluation STudy of diamEter Increase After Vasodilatory Drugs Administration: The TRIESTE Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de recherche clinique - FBM-CHUV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radial artery access use in percutaneous cardiac interventions (PCI) is associated with a
      lower risk of vascular complications, bleeding and major adverse cardiac events including
      cardiac death in the long-term follow-up. Intra-radial administration of vasodilatory drugs,
      transiently painful for the patient, reduces the risk of spasm and is currently the standard
      technique performed worldwide. However, the efficacy of intravenous administration of
      vasodilatory drugs has never been evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center, randomised controlled trial, designed to evaluate the noninferiority of the
      intravenous administration of vasodilatory drugs in comparison with the actual gold standard
      intra-arterial radial route. All consecutive patients with stable ischemic disease or stable
      acute coronary syndrome (NSTEMI - non-st elevation myocardial infarction) for whom a coronary
      procedure is planned will be included in the study.

      Three groups will be constituted. For all groups, the diameters of both radial arteries will
      be measured thrice by echo-Doppler: 5 minutes before sheath insertion, immediately before
      sheath insertion and 5 minutes after sheath insertion. Pain evaluation will be performed
      after injection of the vasodilatory drugs/placebo in the radial artery:

        -  Group 1 (control group): intra-radial administration of the vasodilatory drugs after
           sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)

        -  Group 2 (intravenous-post): intravenous administration of the vasodilatory drugs after
           sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)

        -  Group 3 (intravenous-pre): intravenous administration of the vasodilatory drugs 5
           minutes before sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-center randomised controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal radial artery diameter dilation, measured by echo-doppler, after administration of vasodilatory drugs by intravenous or intra-radial route.</measure>
    <time_frame>5 minutes after vasodilatory drugs administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain evaluation after vasodilatory drugs administration using the intravenous versus intra-radial route</measure>
    <time_frame>Procedure (During vasodilatory drugs administration)</time_frame>
    <description>Scale from 0 to 10, lower values corresponding to lower pain and higher values to intense pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic changes after vasodilatory drugs administration using the intravenous versus intra-radial route</measure>
    <time_frame>5 minutes after vasodilatory drugs administration</time_frame>
    <description>Measure of arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic changes after vasodilatory drugs administration using the intravenous versus intra-radial route</measure>
    <time_frame>5 minutes after vasodilatory drugs administration</time_frame>
    <description>Measure of heart rate.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Arterial Spasm</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Intra-radial group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intra-radial administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous-post group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra-venous administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous-pre group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra-venous administration of the vasodilatory drugs 5 minutes before sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravenous administration of vasodilatory drugs</intervention_name>
    <description>Administration of the vasodilatory drugs in a different pattern than intra-arterially</description>
    <arm_group_label>Intra-radial group</arm_group_label>
    <arm_group_label>Intravenous-post group</arm_group_label>
    <arm_group_label>Intravenous-pre group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical indication for a coronary angiogram by radial route

          -  Age &gt; 18 years old

          -  Chronic coronary disease or stable acute coronary syndrome (NSTEMI, Non-ST Elevation
             Myocardial Infarction)

        Exclusion Criteria:

          -  Refusal of participation in the study

          -  Previous coronary angiography performed by radial route

          -  Presence of verapamil or nitrates in the current pharmacological treatment of the
             patient

          -  STEMI, ST Elevation Myocardial Infarction

          -  Allergy/intolerance to verapamil or nitrates

          -  Severe aortic valvular stenosis

          -  Left ventricular ejection fraction &lt;30%

          -  Heart failure signs or hemodynamic instability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vladimir Rubimbura, MD</last_name>
    <phone>0041795565806</phone>
    <email>vladimir.rubimbura@chuv.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rubimbura Vladimir</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>Vladimir Rubimbura</investigator_full_name>
    <investigator_title>Principal Investigator, Dr Vladimir Rubimbura</investigator_title>
  </responsible_party>
  <keyword>radial spasm</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>vasodilatory drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

